FDA Releases Concept Paper on Pharmacogenomics
After nearly two years of receiving voluntary genomic data submissions as part of its pharmacogenomics guidance, the FDA has released a preliminary concept paper titled Pharmacogenomic Data Submissions.
After nearly two years of receiving voluntary genomic data submissions as part of its pharmacogenomics guidance, the FDA has released a preliminary concept paper titled Pharmacogenomic Data Submissions. The paper expands on the recommendations made in FDA’s guidance for industry on data submissions, issued in March 2005.
Based on its experience with voluntary genomic data submissions and with its review of numerous protocols and data submitted under investigational new drug applications, new drug applications, and biologics license applications during the last two years, FDA believes that guidance will benefit sponsors considering the submission of either voluntary genomic data or marketing applications containing genomics data.
The areas covered in the new document include gene expression data from microarrays including sections on RNA isolation, handling and characterization; labeling reactions, RNA labeling situations to be avoided; proficiency testing to avoid procedural failures; hybridizations for microarrays; fluorescence reader settings for microarrays; and differentially expressed genes and their biological interpretation.
The paper also elaborates on genotyping methods, and DNA isolation, handling and characterization. Genomic data in clinical study reports and from nonclinical toxicology studies, expanding the selection process criteria, and characterization of a particular compound are the other areas covered. A general scientific discussion concludes the paper.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
